2-Week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: A large prospective single-center randomized study

Helicobacter

Volumn 11, Issue 6, 2006, Pages 562-568

  Paoluzi, Paolo ^a,c   Iacopini, Federico ^a   Crispino, Pietro ^a   Nardi, Francesco ^a   Bella, Antonino ^b   Rivera, Margherita ^a   Rossi, Pina ^a   Gurnari, Maurizio ^a   Caracciolo, Francesco ^a   Zippi, Maddalena ^a   Pica, Roberta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

1 week; Eradication; Helicobacter pylori; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UREA BREATH TEST;

ADMINISTRATION, ORAL; AMOXICILLIN; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

HELICOBACTER PYLORI;

EID: 33750545145     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00459.x     Document Type: Article

References (39)

1. Malfertheiner P, Megraud F, O'Morain C, The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
2. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93:2330-8.
3. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxycillin therapy for eradication of Helicobacter pylori: a report from India. Helicobacter 2000;5:84-7.
4. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-66.
5. Kiyota K, Habu Y, Sugano Y, Inokuchi H, Mizuno S, Kimoto K, Kawai K. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxycillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. J Gastroenterol 1999;34:76-9.
6. Dammann HG, Folsch UR, Hahn EG, von Kleist DH, Klor HU, Kirchner T, Strobel S, Kist M. Eradication of Helicobacter pylori with pantoprazole, clarithromycin and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter 2000;5:41-51.
7. Lee JM, Breslin MP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13:489-96.
8. de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of standard side-effects scoring system in studies exploring Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1996;8:641-3.
9. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9.
10. Houben MH, Hensen EF, Rauws EAJ, Hulst RW, Hoff BW, Ende AV, Kate FJ, Tytgat GN. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. Aliment Pharmacol Ther 1999;13:883-9.
11. Qasim A, O'Morain A. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16:24-30.
12. Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
13. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45:68-7.
14. Torracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
15. McNulty C, Owen R, Tompkins D, Hawtin P, McColl K, Price A, Smith G, Teare L, PHLS Helicobacter Working Group. Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrob Chemother 2002;49:601-9.
16. Arents NL, Smeets LC, van Zwet AA, Thijs JC, van der Wouden EJ, de Jong A, Degener JE, Kusters JG. Implications of the simultaneous presence of metronidazole-susceptible and -resistant Helicobacter pylori colonies within a single biopsy specimen. Eur J Clin Microbiol Infect Dis 2001;20:418-20.
17. Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003;8:202-6.
18. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:41-6.
19. Pilotto A, Leandro G, Franceschi M, Rassu M, Bozzola L, Furlan F, Di Mario F, Valerio G. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999;13:667-73.
20. Battaglia G, Di Mario F, Leandro G, Benvenuti ME, Donisi PM, Vianello F, Del Bo N, Pasini M, Pasquino M, Vigneri S. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. Helicobacter 1998;3:115-9.
21. Lind T, Megraud F, Unge P, et al. The MACH2 Study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
22. Neville PM, Barrowclough S, Crocombe W, Axon AT, Wrangstadh M, Moayyedi P. Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients. Digest Liver Dis 2001;33:131-4.
23. Ford A, Moayyedi P. How can current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003;17:36B-40B.
24. Bazzoli F, Porro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002;34:70-83.
25. Fischbach LA, Van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
26. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole-based triple therapy. Aliment Pharmacol Ther 1999;13:289-95.
27. Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-12.
28. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999;159:2312-6.
29. Al-Eiden FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication: the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002;53:163-71.
30. Laurent J, Megraud F, Flejou JF, Caekaert A, Barthelemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1787-93.
31. Savarino A, Zentilin P, Bisso G, Pivari M, Mele MR, Mela GS, Mansi C, Vigneri S, Termini R, Celle G. Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1999;13:643-9.
32. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard Maastricht triple therapy. Aliment Pharmacol Ther 2001;15:1023-9.
33. Bayerdorffer E, Lonovics J, Dite P, et al. Efficacy of two different dosage regimens of omeprazole, amoxicyllin and metronidazole for the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:1639-45.
34. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatments to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
35. Calvet X, Gené E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 2001;15:1067-76.
36. Bardhan KD, Graham DY, Hunt RH, O'Morain CA. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997;2:27-31.
37. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001;13:1303-7.
38. Rudi J, Reuther S, Sieg A, Hoerner M, Stremmel W. Relevance of underlying disease and bacterial vacA and cagA status on the efficacy of Helicobacter pylori eradication. Digestion 2002;65:11-5.
39. de Boer WA, Tytgat GN. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol 2001;13:1281-4.